Freeline Therapeutics Holdings plc (NASDAQ:FRLN) Expected to Post Earnings of -$0.64 Per Share

Brokerages expect Freeline Therapeutics Holdings plc (NASDAQ:FRLN – Get Rating) to post earnings per share of ($0.64) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Freeline Therapeutics’ earnings. The highest EPS estimate is ($0.46) and the lowest is ($0.90). Freeline Therapeutics posted earnings per share of ($0.98) during the same quarter last year, which indicates a positive year-over-year growth rate of 34.7%. The company is scheduled to report its next earnings report on Monday, January 1st.

On average, analysts expect that Freeline Therapeutics will report full-year earnings of ($2.26) per share for the current financial year, with EPS estimates ranging from ($3.51) to ($1.47). For the next fiscal year, analysts anticipate that the business will report earnings of ($1.63) per share, with EPS estimates ranging from ($2.99) to ($0.90). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that that provide coverage for Freeline Therapeutics.

Freeline Therapeutics (NASDAQ:FRLN – Get Rating) last issued its quarterly earnings results on Thursday, March 31st. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.25).

FRLN has been the subject of several analyst reports. Zacks Investment Research cut shares of Freeline Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, April 4th. Morgan Stanley cut shares of Freeline Therapeutics from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, February 1st. Stifel Nicolaus reissued a “buy” rating on shares of Freeline Therapeutics in a research note on Friday, February 11th. Finally, Redburn Partners upgraded Freeline Therapeutics from a “neutral” rating to a “buy” rating in a research report on Friday, January 7th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $11.21.

Hedge funds have recently modified their holdings of the company. Values First Advisors Inc. acquired a new position in shares of Freeline Therapeutics during the 4th quarter worth approximately $46,000. Prospera Financial Services Inc acquired a new stake in shares of Freeline Therapeutics during the 3rd quarter worth about $51,000. Citadel Advisors LLC bought a new stake in shares of Freeline Therapeutics during the 2nd quarter worth about $108,000. Morgan Stanley boosted its holdings in shares of Freeline Therapeutics by 22.9% during the third quarter. Morgan Stanley now owns 41,341 shares of the company’s stock worth $141,000 after acquiring an additional 7,704 shares during the period. Finally, SG Americas Securities LLC acquired a new position in Freeline Therapeutics in the 3rd quarter valued at $163,000. 47.05% of the stock is currently owned by institutional investors.

Shares of FRLN stock opened at $0.90 on Friday. Freeline Therapeutics has a 12 month low of $0.75 and a 12 month high of $15.40. The stock has a 50-day moving average price of $1.03.

About Freeline Therapeutics (Get Rating)

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B.

Featured Articles